Showing 4561-4570 of 5623 results for "".
- Birmingham Research Paves the Way for New Anti-Fibrotic Therapy for Glaucomahttps://modernod.com/news/birmingham-research-paves-the-way-for-new-anti-fibrotic-therapy-for-glaucoma/2478727/Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB, could play a key role in treating open angle glaucoma (OAG). The research, reported in
- Volk Optical Releases ClearPod to Address Mask-Related Fogging During Fundus Examinationshttps://modernod.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/Volk Optical announced the release their newest product, the ClearPod, which aims to solve the problem of mask-related fogging during fundus examinations. This patent-pending design has been created in collaboration with ophthalmologists Bradley Sacher, MD, a cataract specialist, and Jerem
- Study: Hospitals At or Near Full COVID-19 ICU Capacity Increase by 90% Over Past Few Monthshttps://modernod.com/news/study-hospitals-at-or-near-full-covid-19-icu-capacity-increase-by-90-over-past-few-months/2478722/A new study found a 90% increase in hospitals reaching intensive care unit (ICU) capacity from July through December, with rural hospitals facing the biggest capacity issues, according to a FierceHealthcare
- Norlase Receives CE Mark Approval for LION Green Laser Systemhttps://modernod.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/Norlase announced that it has been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase’s compact laser technology into one device. With LION’s untethered and portable design, physicians can move freely between treatm
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban
- Samsara Vision Appoints Three New Members to the Board of Directorshttps://modernod.com/news/samsara-vision-appoints-three-new-members-to-the-board-of-directors/2478712/Samsara Vision, a developer of visual prosthetic devices for patients living with late-stage age-related macular degeneration (AMD), has announced the appointment of three new members to its Board of Directors: Jonathan H. Talamo, MD; Tracy M. Valorie; and David Schiff, joining Thierry Clidiere,
- Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombihttps://modernod.com/news/eyenovia-submits-nda-to-fda-for-pharmacologic-mydriasis-with-mydcombi/2478701/Eyenovia announced that it has submitted a new drug application (NDA) to the FDA for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system. The NDA submission follow
- Three Optometry Practices in Southwest Florida Partner With Private Equity Firm US Eyehttps://modernod.com/news/three-optometry-practices-in-southwest-florida-partner-with-private-equity-firm-us-eye/2478699/Three optometry practices in Southwest Florida—Bayside Eye Center, Fort Myers Eye Center and Valentine Eye Care—have partnered with US Eye and Center For Sight. Financial terms of the deal were not disclosed. Center For Sight is a founding member practice of US Eye, a physician-led,
- Timing of Cataract Removal in Infancy May Affect Glaucoma Riskhttps://modernod.com/news/timing-of-cataract-removal-in-infancy-may-affect-glaucoma-risk/2478700/A decade after undergoing cataract removal in infancy a substantial and increasing proportion of patients develop glaucoma or become glaucoma suspects, according to a secondary analysis of a randomized clinical trial, Reuters reported.
- Iridex Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelineshttps://modernod.com/news/iridex-announces-micropulse-transscleral-laser-therapy-now-accepted-in-the-european-glaucoma-society-guidelines/2478696/Iridex reported that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the Iridex Cyclo G6 Laser System and MicroPulse P3 Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendat